learn Verteporfin
chemical that might completely regrow follicles from hair transplant extractions
Search
forLearn
5 / 34 resultslearn Vascular Endothelial Growth Factor
learn Rapamycin
mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth
learn Overview
learn Epidermal Growth Factor
Research
5 / 1000+ results
research 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?
5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
research A Review on the Clinical Utility of PSA in Cancer Prostate
PSA is best for detecting prostate cancer recurrence and evaluating treatment response.
research Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
research Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
research Clinical and genetic predictors of persistent chemotherapy-induced alopecia despite scalp cooling in breast cancer
Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.
Community Join
5 / 1000+ resultscommunity I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
community Does RU58841 potentially cause cancer?
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
community Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
community Low-Dose Oral Minoxidil Does Not Significantly Affect BP
Low-dose oral minoxidil is used for hair loss and does not significantly affect blood pressure but may increase heart rate and cause hypotensive symptoms. Some users experience side effects like palpitations and shortness of breath, while others find it effective; topical minoxidil with tretinoin is also considered.